Notes
2018 Chinese Yuan
US dollars
Reference
Bao K, et al. Pharmacoeconomic Evaluation of Erlotinib for the Treatment of Pancreatic Cancer. Clinical Therapeutics : 28 May 2021. Available from: URL: http://doi.org/10.1016/j.clinthera.2021.04.012
Rights and permissions
About this article
Cite this article
Erlotinib added to gemcitabine not cost effective for pancreatic cancer. PharmacoEcon Outcomes News 881, 14 (2021). https://doi.org/10.1007/s40274-021-7810-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7810-0